Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
TD is a troublesome and potentially irreversible side effect associated with the use of
neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry
the risk of TD.
The present study proposes that sarizotan is a potential agent for treating
neuroleptic-induced TD based on preliminary data indicating efficacy in the management of
dyskinesias associated with Parkinson's disease. Its efficacy is further substantiated by
pre-clinical data obtained from the vacuous chewing movement (VCM) model in rats, a model we
employ ourselves in investigating the relationship between D2 occupancy and TD. The present
study also examines the effects of sarizotan on cognitive function, given the association
between TD and cognitive deficits.